{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:06:43Z","timestamp":1769756803472,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clml.2019.09.612","type":"journal-article","created":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T18:18:54Z","timestamp":1569694734000},"page":"791-798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use"],"prefix":"10.1016","volume":"19","author":[{"given":"Mitchell E.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Landsburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James N.","family":"Gerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esin","family":"Namoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.09.612_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib2","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classification of non-Hodgkin\u2019s lymphomas: summary and description of working formulation for clinical usage. The Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project","volume":"49","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.09.612_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.09.612_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.09.612_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib6","first-page":"2821","article-title":"Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: results from a randomized phase 2 study","volume":"130","author":"Sehn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2019.09.612_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.09.612_bib9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.09.612_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.09.612_bib11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.612_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood.V126.23.255.255","article-title":"A\u00a0dose-escalation study of venetoclax (ABT-199\/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"126","author":"de Vos","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.612_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.clml.2019.09.612_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clml.2017.10.004","article-title":"A\u00a0systematic review of treatments of relapsed\/refractory mantle cell lymphoma","volume":"18","author":"Crump","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.09.612_bib16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.612_bib17","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib18","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1128\/JVI.03179-15","article-title":"Prime, shock, and kill: priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size","volume":"90","author":"Cummins","year":"2016","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clml.2019.09.612_bib19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4049\/jimmunol.181.1.521","article-title":"The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages","volume":"181","author":"Dzhagalov","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2019.09.612_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2017-04-737338","article-title":"Targeting BCL-2 in B-cell lymphomas","volume":"130","author":"Davids","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib21","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/annonc\/mdw029","article-title":"Breakthrough therapies in B-cell non-Hodgkin lymphoma","volume":"27","author":"Cheah","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.clml.2019.09.612_bib22","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1016\/j.clml.2017.07.097","article-title":"Modified venetoclax dose ramp-up in select high-risk patients with chronic lymphocytic leukemia (CLL) with progression after B-cell receptor pathway inhibitors (BCRi)","volume":"17","author":"Davids","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.09.612_bib23","first-page":"PF357","article-title":"Rapid dose escalation of venetoclax in patients with chronic lymphocytic leukemia previously treated with B-cell receptor inhibitor therapy","volume":"214830","author":"Koenig","year":"2018","journal-title":"Eur Hematol Assoc"},{"key":"10.1016\/j.clml.2019.09.612_bib24","series-title":"Venclexta (Venetoclax) [Prescribing Information]","year":"2018"},{"key":"10.1016\/j.clml.2019.09.612_bib25","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.18.00359","article-title":"Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma","volume":"36","author":"Davids","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.612_bib26","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2018-99-113777","article-title":"Ibrutinib plus obinutuzumab and venetoclax in relapsed\/refractory mantle cell lymphoma: patients, results of the OASIS phase I clinical trial","volume":"132","author":"Gouill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib27","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","volume":"133","author":"Morschhauser","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib28","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood.V128.22.617.617","article-title":"Phase 2 study of venetoclax plus rituximab or randomized Ven plus bendamustine\u00a0+ rituximab (BR) versus BR in patients with relapsed\/refractory follicular lymphoma: interim data","volume":"128","author":"Zinzani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib30","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","volume":"29","author":"de Vos","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.09.612_bib31","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/blood-2018-99-117172","article-title":"Preliminary results of a phase I study of obinutuzumab, venetoclax, and lenalidomide in relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.612_bib32","first-page":"088","article-title":"Initial results of a multicenter phase 2 study of venetoclax in combination with dose-adjusted R-EPOCH for patients with Richter\u2019s syndrome (CRC-043)","volume":"132","author":"Davids","year":"2019","journal-title":"Hematol Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019319998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019319998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:02Z","timestamp":1761870842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019319998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S2152265019319998"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.612","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}